Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

被引：37
|
作者：
Isakoff, Steven J. [1 ]
Baselga, Jose [1 ]
机构：
[1] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
MONOCLONAL-ANTIBODY; ADJUVANT CHEMOTHERAPY; INHIBITOR; PLUS; COMBINATION; PERTUZUMAB; LAPATINIB; EFFICACY; THERAPY; COMPLEX;
D O I：
10.1200/JCO.2010.31.6679
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：351 / 354
页数：4
相关论文
共 50 条
  • [41] New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023
    Banys-Paluchowski, Maggie
    Krawczyk, Natalia
    Stickeler, Elmar
    Mueller, Volkmar
    Fehm, Tanja
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2023, 35 (01) : 54 - 61
  • [42] Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
    Lv, Huimin
    Yan, Min
    Jiang, Zefei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [43] Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? comment
    Tarantino, Paolo
    Tolaney, Sara M.
    Harbeck, Nadia
    Cortes, Javier
    Curigliano, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (32) : 3541 - +
  • [44] Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer
    Miller, Kathy D.
    Dieras, Veronique
    Harbeck, Nadia
    Andre, Fabrice
    Mahtani, Reshma L.
    Gianni, Luca
    Albain, Kathy S.
    Crivellari, Diana
    Fang, Liang
    Michelson, Glenn
    de Haas, Sanne L.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (14) : 1437 - +
  • [45] Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
    Gupta, Manish
    Wang, Bei
    Carrothers, Timothy J.
    LoRusso, Patricia M.
    Chu, Yu-Waye
    Shih, Ted
    Loecke, David
    Joshi, Amita
    Saad, Ola
    Yi, Joo-Hee
    Girish, Sandhya
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (01): : 11 - 24
  • [46] Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review
    Zhang, Xiao
    Zhang, Xin-Ji
    Zhang, Tian-Yi
    Yu, Fei-Fei
    Wei, Xin
    Li, Ye-Sheng
    He, Jia
    BMC CANCER, 2014, 14
  • [47] Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives
    Dormann, Clemens
    BREAST CARE, 2020, 15 (06) : 570 - 578
  • [48] Abundant options to avoid toxicity and alternative strategies for human epidermal growth factor receptor 2-positive and hormone receptor-positive advanced breast cancer
    Araki, Kazuhiro
    Miyoshi, Yasuo
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S514 - S518
  • [49] Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade and Hormonal Therapy for the Treatment of Primary HER2-Positive Breast Cancer: One More Step Toward Chemotherapy-Free Therapy
    Prat, Aleix
    Baselga, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) : 1703 - 1706
  • [50] GEMOX: An Active Regimen for the Treatment of Luminal and Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
    Rizzi, Anna
    Aroldi, Francesca
    Bertocchi, Paola
    Prochilo, Tiziana
    Mutti, Stefano
    Savelli, Giordano
    Fraccon, Anna Paola
    Zaniboni, Alberto
    CHEMOTHERAPY, 2017, 62 (01) : 30 - 33
12345